The division of rare diseases research innovation at the national center for advancing translational sciences, NIH: mission, history, and current research activities

Abstract

The mission of the NCATS Division of Rare Diseases Research Innovation (DRDRI), formerly known as the Office of Rare Diseases Research, is to advance rare diseases research to benefit patients. DRDRI is part of the National Center for Advancing Translational Sciences, one of the 27 components of the US National Institutes of Health. DRDRI facilitates and coordinates NIH-wide activities involving rare diseases research, as well as directly supporting rare diseases research activities. These activities include the development and maintenance of a centralized database on rare diseases; collaboration and coordination with organizations focused on orphan products development and rare diseases research across the globe, advising the Office of the NIH Director on matters related to NIH-sponsored research involving rare diseases; and responding to information and policy requests about rare diseases within the NIH. DRDRI also supports various rare diseases research activities, including the Rare Diseases Clinical Research Network, rare disease-related conference grants, and assessment of the costs of untreated rare diseases. In addition, several of the projects DRDRI is supporting are “many diseases at a time” translational approaches for rare diseases, which emphasize leveraging commonalities across multiple rare diseases. These include the support of “basket trials” based on shared molecular etiologies across multiple rare diseases, as well as therapeutic platforms for the treatment of monogenic diseases, such as gene therapy and genome editing. This Perspective will provide an overview and summary of these various activities, noting where relevant our collaborative partnerships within the U.S. and internationally.

Keywords

Clinical research readiness / genetic disease / diagnostic odyssey / translational research / research funding

References

[1] RARE-X. The power of being counted. 2022. Available from: https://rare-x.org/case-studies/the-power-of-being-counted/ [Last accessed on 3 Jun 2024].

[2] Haendel M,Unni D.How many rare diseases are there?.Nat Rev Drug Discov2020;19:77-8 PMCID:PMC7771654

[3] Garrison S,Manetto N,Rutter JL.The economic burden of rare diseases: quantifying the sizeable collective burden and offering solutions. Health Affairs Forefront. 2022.

[4] Tisdale A,Nathan R.The IDeaS initiative: pilot study to assess the impact of rare diseases on patients and healthcare systems.Orphanet J Rare Dis2021;16:429 PMCID:PMC8532301

[5] Navarrete-Opazo AA,Tisdale A,Garrison SR.Can you hear us now? The impact of health-care utilization by rare disease patients in the United States.Genet Med2021;23:2194-201 PMCID:PMC8553605

[6] Kariampuzha WZ,Qu S.Precision information extraction for rare disease epidemiology at scale.J Transl Med2023;21:157

[7] Zhu Q,Liu R.Rare disease-based scientific annotation knowledge graph.Front Artif Intell2022;5:932665 PMCID:PMC9403737

[8] Lumsden JM.The rare diseases clinical research network: a model for clinical trial readiness.Ther Adv Rare Dis2023;4:26330040231219272 PMCID:PMC10752072

[9] Cortese A,Rebelo AP.Biallelic mutations in SORD cause a common and potentially treatable hereditary neuropathy with implications for diabetes.Nat Genet2020;52:473-81

[10] Applied Therapeutics. Applied therapeutics announces initiation of registrational phase 2/3 study of AT-007 in SORD deficiency. 2021. Available from: https://ir.appliedtherapeutics.com/news-releases/news-release-details/applied-therapeutics-announces-initiation-registrational-phase [Last accessed on 3 Jun 2024].

[11] Applied Therapeutics. Applied therapeutics announces positive sorbitol reduction data from the ongoing phase 3 INSPIRE trial in sorbitol dehydrogenase (SORD) deficiency. 2023. Available from: https://ir.appliedtherapeutics.com/news-releases/news-release-details/applied-therapeutics-announces-positive-sorbitol-reduction-data

[12] Nguengang Wakap S,Olry A.Estimating cumulative point prevalence of rare diseases: analysis of the Orphanet database.Eur J Hum Genet2020;28:165-73 PMCID:PMC6974615

[13] Beaverson KL,Letinturier MCV.The IRDiRC chrysalis task force: making rare disease research attractive to companies.Ther Adv Rare Dis2023;4:26330040231188979 PMCID:PMC10387802

[14] Brooks PJ,Groft S.Expanding rare disease drug trials based on shared molecular etiology.Nat Biotechnol2014;32:515-8 PMCID:PMC4548299

[15] Park JJH,Siden EG,Mills EJ.An overview of precision oncology basket and umbrella trials for clinicians.CA Cancer J Clin2020;70:125-37 PMCID:PMC7187272

[16] Zanello G,Crespo A.Targeting shared molecular etiologies to accelerate drug development for rare diseases.EMBO Mol Med2023;15:e17159 PMCID:PMC10331571

[17] Lomash RM,Chandler RJ,Pariser AR.NIH PaVe-GT TeamSuccessfully navigating food and drug administration orphan drug and rare pediatric disease designations for AAV9-hPCCA gene therapy: the national institutes of health platform vector gene therapy experience.Hum Gene Ther2023;34:217-27 PMCID:PMC10031144

[18] Table of contents, volume 193, number 1, March 2023.Am J Med Genetics2023;193:1-2

[19] Yu TW,Green RC.Are we prepared to deliver gene-targeted therapies for rare diseases?.Am J Med Genet C Semin Med Genet2023;193:7-12

[20] Gaviglio AM,Lou LJ,Augustine EF.Gene-targeted therapies: towards equitable development, diagnosis, and access.Am J Med Genet C Semin Med Genet2023;193:56-63

[21] Vockley J,Cohen JL.Whole-genome sequencing holds the key to the success of gene-targeted therapies.Am J Med Genet C Semin Med Genet2023;193:19-29

[22] Garrison LP Jr,Finkel RS.A review of economic issues for gene-targeted therapies: value, affordability, and access.Am J Med Genet C Semin Med Genet2023;193:64-76